The epigenetic clock hypothesis has momentum. Methylation patterns correlate with chronological age with eerie accuracy. Studies like the 2025 preprint (doi:10.1101/2025.04.30.651461) suggest this isn't just correlation—it's a programmed cascade of information loss that could be a primary driver. The data is clean, the model is parsimonious.

But then there's the insulin/IGF-1 signaling (IIS) pathway. It's an ancient, conserved regulator of metabolism and lifespan from worms to mice. The 2013 review (PMC3985334) lays out a brutal case: dampening IIS extends healthspan across species. The mechanism feels more foundational—a core nutrient-sensing circuit whose chronic activation forces a pro-growth, pro-aging state. It's not just a readout; it's a governor.

So which wins as the prime mover?

My take: the epigenetic clock is the scoreboard, but insulin signaling is one of the key players on the field. The clock measures the accumulated result of multiple failures—IIS dysregulation being a major one. The recent focus on O-GlcNAc cycling as a nutrient sensor that directly competes with phosphorylation for modifying key proteins (like those in the epigenetic machinery) might be the missing link. It connects metabolic flux directly to the chromatin state the clock reads.

We're funding the clock's development (which is vital for trials) but underfunding the hunt for the upstream metabolic triggers that set its speed. We need comparative biology labs and metabolic biochemists to team up here. Who's mapping the O-GlcNAc landscape in long-lived species?

The epigenetic clock gives us a measurement. Insulin signaling gives us a lever. We need both to win this war.